Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/196614
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGil Lespinard, Mercedes-
dc.contributor.authorBambarén Capurro, Carlos-
dc.contributor.authorMontserrat, Mónica-
dc.contributor.authorVirgili Casas, Núria-
dc.contributor.authorZamora-Ros, Raul-
dc.date.accessioned2023-04-12T11:09:48Z-
dc.date.available2023-04-12T11:09:48Z-
dc.date.issued2022-12-01-
dc.identifier.issn2451-8654-
dc.identifier.urihttp://hdl.handle.net/2445/196614-
dc.description.abstractBackground: Morbid obesity (body mass index >= 40 kg/m2) represents a severe health risk and implies the need of urgent therapeutic action. (Poly)phenols may play a relevant role in the management of this disease modulating physiological and molecular pathways involved in energy metabolism and adiposity. The purpose of this double -blinded, placebo-controlled, randomised trial is to determine if (poly)phenol supplementation, in combination with a dietary intervention, can improve anthropometric and cardiometabolic parameters in participants with morbid obesity. Methods: Adults (n = 40) with morbid obesity, bariatric surgery candidates, will be recruited from the Bellvitge University Hospital, Spain, and randomly assigned (stratified by sex) to intervention (poly)phenol-rich supple-ment 1,200 mg/day + hypocaloric diet) or control group (placebo + hypocaloric diet) for 12 weeks. The primary outcome is body weight. Secondary outcomes are: other anthropometric markers and body composition measured through standardized methods and a bioimpedance analysis, cardiometabolic and inflammatory bio-markers, metabolic pathways, and gut microbiota diversity. Anthropometric parameters, dietary, physical ac-tivity and lifestyle questionnaires, blood pressure, and blood and urine samples will be collected at baseline, 6 weeks, and 12 weeks. Faecal samples will be collected at baseline and at 12 weeks. Informed consent of par-ticipants will be obtained before the start of the study.Discussion:: The present study is expected to provide evidence on the effects of a combination of (poly)phenols on several well-established obesity and cardiometabolic markers, and to unravel possible underlying mechanisms by metabolomic analyses. Gut microbiota diversity will be considered as a potential future endpoint. The study will contribute to future strategies for prevention or treatment of obesity and related conditions.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier BV-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.conctc.2022.101034-
dc.relation.ispartofContemporary Clinical Trials Communications, 2022, vol. 30, p. 101034-
dc.relation.urihttps://doi.org/10.1016/j.conctc.2022.101034-
dc.rightscc by-nc-nd (c) Gil Lespinard, Mercedes et al., 2022-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)-
dc.subject.classificationObesitat mòrbida-
dc.subject.classificationAssaigs clínics-
dc.subject.classificationMarcadors bioquímics-
dc.subject.classificationMetabolòmica-
dc.subject.otherMorbid obesity-
dc.subject.otherClinical trials-
dc.subject.otherBiochemical markers-
dc.subject.otherMetabolomics-
dc.titleEffects of a (poly)phenol-rich supplement on anthropometric, biochemical, and inflammatory parameters in participants with morbid obesity: Study protocol for a randomised controlled trial-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2023-04-06T15:00:10Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid36387986-
Appears in Collections:Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
main (3).pdf1.69 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons